Papillary microcarcinoma of the thyroid gland: Is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease?

Acta Oncologica

Volumn 47, Issue 3, 2008, Pages 451-457

  Londero, Stefano Christian ^a   Godballe, Christian ^a   Krogdahl, Annelise ^a   Bastholt, Lars ^a   Specht, Lena ^b   Sørensen, Christian Hjort ^c   Pedersen, Henrik Baymler ^d   Pedersen, Ulrik ^e   Christiansen, Peer ^e  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; GALECTIN 3;

ADULT; ARTICLE; CANCER REGISTRY; CANCER SIZE; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROMETASTASIS; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFERENCE DATABASE; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; THYROID CARCINOMA; TISSUE SECTION; WORLD HEALTH ORGANIZATION;

ADULT; CARCINOMA, PAPILLARY; CYCLINS; DATABASES, FACTUAL; DENMARK; FEMALE; GALECTIN 3; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 40949152879     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701630242     Document Type: Article

References (23)

1. Muro-Cacho CA, Holt T, Klotch D, Mora L, Livingston S, Futran N. Cyclin D1 expression as a prognostic parameter in papillary carcinoma of the thyroid. Otolaryngol Head Neck Surg 1999;120:200-7.
2. Neumeister P, Pixley FJ, Xiong Y, Xie H, Wu K, Ashton A, et al. Cyclin D1 governs adhesion and motility of macrophages. Mol Biol Cell 2003;14:2005-15.
3. Frierson HF Jr, Gaffey MJ, Zukerberg LR, Arnold A, Williams ME. Immunohistochemical detection and gene amplification of cyclin D1 in mammary infiltrating ductal carcinoma. Mod Pathol 1996;9:725-30.
4. Wang S, Lloyd RV, Hutzler MJ, Safran MS, Patwardhan NA, Khan A. The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Mod Pathol 2000;13:882-7.
5. Basolo F, Caligo MA, Pinchera A, Fedeli F, Baldanzi A, Miccoli P, et al. Cyclin D1 overexpression in thyroid carcinomas: Relation with clinico-pathological parameters, retinoblastoma gene product, and Ki67 labeling index. Thyroid 2000;10:741-6.
6. Saiz AD, Olvera M, Rezk S, Florentine BA, McCourty A, Brynes RK. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J Pathol 2002;198:157-62.
7. Pickett CA, Agoff SN, Widman TJ, Bronner MP. Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: Prognostic implications. Thyroid 2005;15:461-73.
8. Khoo ML, Beasley NJ, Ezzat S, Freeman JL, Asa SL. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 2002;87:1814-8.
9. Lantsov D, Meirmanov S, Nakashima M, Kondo H, Saenko V, Naruke Y, et al. Cyclin D1 overexpression in thyroid papillary microcarcinoma: Its association with tumour size and aberrant beta-catenin expression. Histopathology 2005;47:248-56.
10. Khoo ML, Ezzat S, Freeman JL, Asa SL. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab 2002;87:1810-3.
11. Ito Y, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, et al. Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination. Oncology 2005;68:87-96.
12. Califice S, Castronovo V, Van Den BF. Galectin-3 and cancer (Review). Int J Oncol 2004;25:983-92.
13. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001;357:1644-50.
14. Coli A, Bigotti G, Zucchetti F, Negro F, Massi G. Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology 2002;40:80-7.
15. Feilchenfeldt J, Totsch M, Sheu SY, Robert J, Spiliopoulos A, Frilling A, et al. Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry. Mod Pathol 2003;16:1117-23.
16. Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG, Bartolazzi A. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol 1999;17:3494-502.
17. Kovacs RB, Foldes J, Winkler G, Bodo M, Sapi Z. The investigation of galectin-3 in diseases of the thyroid gland. Eur J Endocrinol 2003;149:449-53.
18. Mehrotra P, Okpokam A, Bouhaidar R, Johnson SJ, Wilson JA, Davies BR, et al. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 2004;45:493-500.
19. Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 2000;31:428-33.
20. Cvejic D, Savin S, Petrovic I, Paunovic I, Tatic S, Krgovic K, et al. Galectin-3 expression in papillary microcarcinoma of the thyroid. Histopathology 2005;47:209-14.
21. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001;357:1644-50.
22. Mehrotra P, Okpokam A, Bouhaidar R, Johnson SJ, Wilson JA, Davies BR, et al. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 2004;45:493-500.
23. Cvejic D, Savin S, Petrovic I, Paunovic I, Tatic S, Krgovic K, et al. Galectin-3 expression in papillary microcarcinoma of the thyroid. Histopathology 2005;47:209-14.